Severe acute respiratory syndrome-coronavirus-2: Current advances in therapeutic targets and drug development

Rev Med Virol. 2021 May;31(3):e2174. doi: 10.1002/rmv.2174. Epub 2020 Sep 23.

Abstract

The current pandemic of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) has quickly emerged as a global health concern with government bodies worldwide taking drastic control measures. Understanding the virology of SARS-CoV-2, its molecular mechanisms, and its pathogenesis are required for a targeted therapeutic approach. In this review, we highlight the current molecular and drug advances that target SARS-CoV-2 at the genome level. We also summarize studies that therapeutically target the host angiotensin-converting enzyme 2 and proteases. Finally, we summarize antibody-mediated therapeutic approaches, as well as recent trends in vaccine development. Hence, the purpose of this study is to investigate different molecular targets in SARS-CoV-2 pathogenesis and their usefulness in developing strategies for drug development.

Keywords: ACE2; SARS-CoV-2; TMPRSS2; antibodies; vaccine development; virus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiotensin-Converting Enzyme 2 / antagonists & inhibitors
  • Angiotensin-Converting Enzyme 2 / genetics*
  • Angiotensin-Converting Enzyme 2 / immunology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Viral / therapeutic use
  • Antiviral Agents / chemical synthesis
  • Antiviral Agents / therapeutic use
  • COVID-19 / immunology
  • COVID-19 / prevention & control
  • COVID-19 / therapy
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • COVID-19 Serotherapy
  • Coronavirus 3C Proteases / antagonists & inhibitors*
  • Coronavirus 3C Proteases / chemistry
  • Coronavirus 3C Proteases / genetics
  • Coronavirus 3C Proteases / metabolism
  • Drug Approval
  • Drug Discovery
  • Gene Expression Regulation
  • Host-Pathogen Interactions / genetics
  • Host-Pathogen Interactions / immunology
  • Humans
  • Immunization, Passive / methods
  • Protease Inhibitors / chemical synthesis
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / immunology
  • SARS-CoV-2 / pathogenicity
  • Serine Endopeptidases / genetics*
  • Serine Endopeptidases / immunology
  • Spike Glycoprotein, Coronavirus / antagonists & inhibitors
  • Spike Glycoprotein, Coronavirus / genetics*
  • Spike Glycoprotein, Coronavirus / immunology
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Antiviral Agents
  • Protease Inhibitors
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2
  • Serine Endopeptidases
  • TMPRSS2 protein, human
  • Coronavirus 3C Proteases